UCB's Roch Doliveux joins Board of the Innovative Medicines Initiative | UCB
UCB's Global Corporate Website

This section is intended for media and financial analysts

UCB's Roch Doliveux joins Board of the Innovative Medicines Initiative

Appointment confirms UCB's commitment to this unique public-private partnership

Brussels (Belgium), May 18, 2010 - press release - UCB announced today that CEO Roch Doliveux has joined the Governing Board of the Innovative Medicines Initiative (IMI), a public-private partnership between the European Union and the European Federation of Pharmaceutical Industries and Associations (EFPIA), of which UCB has been a member since its initiation in 2006.

The goal of the IMI is to improve the environment for biomedical research and development in Europe and to promote innovation through open collaboration. With its unique and innovative funding mechanism, IMI supports research to speed up the development of better and safer medicines for patients. The European Commission contributes €1 billion to the IMI via its Seventh Framework Programme. This amount is matched by in-kind contributions of at least another €1 billion euro from EFPIA member companies.

"One of UCB's strategies is 'Partnering to increase value and efficiency'. This statement of belief is at the heart of the IMI," says Roch Doliveux. "As a leading player in European biomedical research, and through our collaboration with the top-quality consortia established within IMI, we are working to improve the efficiency of the industry in bringing safe, efficacious, cost-effective treatments to patients. The collaborative programmes within IMI allow the partners to share pre-competitive data that support drug discovery efforts, bringing not just efficiencies, but also societal and socio-economic benefits."

UCB is a significant contributor to the Innovative Medicines Initiative, and is participating in 10 of the 15 initial consortia within IMI. UCB is providing expert input on topics including neurodegenerative disorders, pain research, immunogenicity, predictive toxicology, pharmacovigilance, translational safety biomarkers, and strategies for treating Chronic Obstructive Pulmonary Disease, as well as a number of training programmes.

Beyond IMI, UCB is partnering widely with academic and industrial research organisations, to increase value and efficiency, and to stimulate innovation. UCB now has several hundred collaborative alliances, ranging from partnerships with European and US academic groups, to multiple industrial partnerships, and membership of major government-led consortia. Reflecting the location of UCB's research 'hubs', the network of academic collaboration is most extensive in Belgium, Germany and the UK where UCB has over 150 partnerships with academic institutions.


Notes to Editors:


Roch Doliveux joined UCB in October 2003 as Director General of the Pharma Sector and Deputy Chairman of the Executive Committee. He became CEO and Chairman of the Executive Committee of UCB Group on January 1, 2005. He is a member of the Board of Directors of UCB, as well as a member of the Board of the European Federation of Pharmaceutical Association (EFPIA), of the INSEAD International Council, the Science & Business Innovation Board, the Caring Entrepreneurship Fund (King Baudouin Foundation) and WELBIO (Walloon Institute for Life Lead Sciences).

* The Innovative Medicines Initiative Joint Undertaking (IMI JU) is the largest public-private partnership in the area of medical research. It is an innovative collaboration established between the European Commission and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The objective is to make the drug discovery and development process more efficient, to bring safer and better medicines faster to patients, and to boost biomedical innovation in Europe. For more information, visit www.imi.europa.eu

For further information
Nancy Nackaerts, External Communications, UCB
T +32.473.864.414 or +32.2.559.92.64, nancy.nackaerts@ucb.com

About UCB
UCB, Brussels, Belgium (www.ucb.com) is a biopharmaceutical company dedicated to the research, development and commercialization of innovative medicines with a focus on the fields of central nervous system and immunology disorders. Employing more than 9 000 people in over 40 countries, UCB produced revenue of EUR 3.1 billion in 2009. UCB is listed on Euronext Brussels (symbol: UCB).

Forward looking statement

This press release contains forward-looking statements based on current plans, estimates and beliefs of management. Such statements are subject to risks and uncertainties that may cause actual results to be materially different from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, effects of future judicial decisions, changes in regulation, exchange rate fluctuations and hiring and retention of its employees.

Asset Download

Stay up-to-date on the latest news and information from UCB